Triveni Bio is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. It combines a Mendelian genetics-informed precision medicine approach with advanced antibody engineering to identify targets and build functional antibodies. Its pipeline includes TRIV-509, a dual kallikreins 5 and 7 inhibitor in Phase 2 for atopic dermatitis; TRIV-573, a bispecific antibody targeting KLK5/7 and interleukin 13; and TRIV-920, a first-in-class dual trypsin 1 and 2 inhibitor in preclinical development for pancreatitis.
Founded in 2023 through the merger of Amagma Therapeutics and Modify Therapeutics, Triveni Bio is headquartered in Watertown, Massachusetts. The company has raised over $272 million across three funding rounds, including a $92 million Series A, a $115 million Series B, and a $65 million Series C co-led by Ascenta Capital and Janus Henderson Investors in June 2026. Triveni Bio is led by CEO Vishal Patel, PhD, Chief Medical Officer Bhaskar Srivastava, MD, PhD, and Chief Scientific Officer Jennifer Dovey, PhD.
